Adi Barzel

1.3k total citations · 1 hit paper
18 papers, 919 citations indexed

About

Adi Barzel is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Adi Barzel has authored 18 papers receiving a total of 919 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 9 papers in Genetics and 7 papers in Oncology. Recurrent topics in Adi Barzel's work include CRISPR and Genetic Engineering (10 papers), Virus-based gene therapy research (8 papers) and CAR-T cell therapy research (6 papers). Adi Barzel is often cited by papers focused on CRISPR and Genetic Engineering (10 papers), Virus-based gene therapy research (8 papers) and CAR-T cell therapy research (6 papers). Adi Barzel collaborates with scholars based in Israel, United States and Italy. Adi Barzel's co-authors include Martin Kupiec, Mark A. Kay, Yuanhua Huang, K. Chu, K M Gaensler, Yun Shi, Nicole K. Paulk, Matthew H. Porteus, Laura Spector and Paul N. Valdmanis and has published in prestigious journals such as Nature, Nucleic Acids Research and Nature Communications.

In The Last Decade

Adi Barzel

16 papers receiving 897 citations

Hit Papers

Frequent aneuploidy in primary human T cells after CRISPR... 2022 2026 2023 2024 2022 40 80 120

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adi Barzel Israel 15 754 423 180 80 75 18 919
Ewa P. Malc United States 20 1.5k 2.0× 299 0.7× 199 1.1× 39 0.5× 86 1.1× 28 1.8k
Hideyo Ugai Japan 18 895 1.2× 473 1.1× 216 1.2× 85 1.1× 97 1.3× 47 1.1k
Nina Tonnu United States 5 829 1.1× 225 0.5× 153 0.8× 72 0.9× 108 1.4× 5 954
David A. Shivak United States 9 856 1.1× 508 1.2× 192 1.1× 35 0.4× 57 0.8× 10 1.0k
Martijn J. W. E. Rabelink Netherlands 16 599 0.8× 384 0.9× 193 1.1× 86 1.1× 73 1.0× 30 855
Anna Gil United States 11 480 0.6× 118 0.3× 80 0.4× 75 0.9× 217 2.9× 17 819
Haley M. Amemiya United States 8 907 1.2× 230 0.5× 63 0.3× 21 0.3× 113 1.5× 11 1.1k
Alexandre Akoulitchev United Kingdom 16 1.3k 1.8× 87 0.2× 78 0.4× 92 1.1× 129 1.7× 35 1.6k
Peter M. Dierks United States 10 844 1.1× 293 0.7× 117 0.7× 58 0.7× 202 2.7× 13 1.2k
Timm Weber Germany 10 1.2k 1.6× 369 0.9× 187 1.0× 113 1.4× 146 1.9× 14 1.5k

Countries citing papers authored by Adi Barzel

Since Specialization
Citations

This map shows the geographic impact of Adi Barzel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adi Barzel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adi Barzel more than expected).

Fields of papers citing papers by Adi Barzel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adi Barzel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adi Barzel. The network helps show where Adi Barzel may publish in the future.

Co-authorship network of co-authors of Adi Barzel

This figure shows the co-authorship network connecting the top 25 collaborators of Adi Barzel. A scholar is included among the top collaborators of Adi Barzel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adi Barzel. Adi Barzel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Bracha, Moshe, S. Shavit, Roy Avraham, et al.. (2025). Mouse B cells engineered to express an anti-HPV antibody elicit anti-tumor T cell responses.. PubMed. 16. 1613879–1613879.
3.
Nahmad, Alessio D., Cícera R. Lazzarotto, Talia Kustin, et al.. (2022). In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice. Nature Biotechnology. 40(8). 1241–1249. 52 indexed citations
4.
Nahmad, Alessio D., Eli Reuveni, Tamar Tenne, et al.. (2022). Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage. Nature Biotechnology. 40(12). 1807–1813. 122 indexed citations breakdown →
5.
Marais, Thibaut, Elena Barbon, Maria Grazia Biferi, et al.. (2022). Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice. SHILAP Revista de lepidopterología. 4. 785698–785698. 16 indexed citations
6.
Dror, Yael, et al.. (2021). Antibody Repertoire Analysis of Tumor-Infiltrating B Cells Reveals Distinct Signatures and Distributions Across Tissues. Frontiers in Immunology. 12. 705381–705381. 13 indexed citations
7.
Nahmad, Alessio D., Yuval Raviv, Miriam Horovitz‐Fried, et al.. (2020). Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion. Nature Communications. 11(1). 5851–5851. 52 indexed citations
8.
Chandler, Randy J., Brandon T. Hubbard, Jessica L. Schneller, et al.. (2020). Promoterless, Nuclease‐Free Genome Editing Confers a Growth Advantage for Corrected Hepatocytes in Mice With Methylmalonic Acidemia. Hepatology. 73(6). 2223–2237. 43 indexed citations
9.
Porro, Fabiola, Giulia Bortolussi, Adi Barzel, et al.. (2019). Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases. JCI Insight. 4(15). 46 indexed citations
10.
Porro, Fabiola, Giulia Bortolussi, Adi Barzel, et al.. (2017). Promoterless gene targeting without nucleases rescues lethality of a Crigler‐Najjar syndrome mouse model. EMBO Molecular Medicine. 9(10). 1346–1355. 47 indexed citations
11.
Borel, Florie, Qiushi Tang, Gwladys Gernoux, et al.. (2017). Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of α-1 Antitrypsin Deficiency. Molecular Therapy. 25(11). 2477–2489. 55 indexed citations
12.
Nygaard, Sean, Adi Barzel, Annelise Haft, et al.. (2016). A universal system to select gene-modified hepatocytes in vivo. Science Translational Medicine. 8(342). 342ra79–342ra79. 39 indexed citations
13.
Barzel, Adi, Nicole K. Paulk, Yun Shi, et al.. (2014). Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature. 517(7534). 360–364. 198 indexed citations
14.
Barzel, Adi, Uri Obolski, J. Peter Gogarten, Martin Kupiec, & Lilach Hadany. (2011). Home and away- the evolutionary dynamics of homing endonucleases. BMC Evolutionary Biology. 11(1). 324–324. 20 indexed citations
15.
Naor, Adit, et al.. (2011). In Vivo Characterization of the Homing Endonuclease within the polB Gene in the Halophilic Archaeon Haloferax volcanii. PLoS ONE. 6(1). e15833–e15833. 18 indexed citations
16.
Barzel, Adi, Eyal Privman, Adit Naor, et al.. (2011). Native homing endonucleases can target conserved genes in humans and in animal models. Nucleic Acids Research. 39(15). 6646–6659. 21 indexed citations
17.
Barzel, Adi, Adit Naor, Eyal Privman, Martin Kupiec, & Uri Gophna. (2011). Homing endonucleases residing within inteins: evolutionary puzzles awaiting genetic solutions. Biochemical Society Transactions. 39(1). 169–173. 29 indexed citations
18.
Barzel, Adi & Martin Kupiec. (2007). Finding a match: how do homologous sequences get together for recombination?. Nature Reviews Genetics. 9(1). 27–37. 148 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026